Navigation Links
Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors

CAMBRIDGE, Mass., Nov. 29 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and development of novel treatments for autoimmune disease and cancer, today announced the retirement of Steven C. Wheelwright, PhD from its Board of Directors and the addition of Robert Gay, PhD.

Dr. Wheelwright served as a Director at Merrimack since May 2006. He was recently named the President of Brigham Young University Hawaii and is stepping down due to his relocation. Most recently, Dr. Wheelwright served as a Baker Foundation Professor and Chairman of HBS Publishing at Harvard Business School, while serving on numerous boards including Merrimack.

"Steve was an invaluable resource for our Board and the management at Merrimack," said Gary Crocker, Chairman of Merrimack's Board of Directors. "He was an outstanding director that provided the Board and management with pharmaceutical and operations expertise. We congratulate him and wish him the best in his new position."

Dr. Gay joins Merrimack's board having served as the former Managing Director and Chairman of the Management Committee of Bain Capital. Bain Capital is one of the world's leading private equity firms with over $40 billion in capital with offices in the US, Asia and Europe. Prior to joining Bain, Dr. Gay held numerous high level positions including Executive Vice President of General Electric Credit Corporation's Capital Markets Group, Vice President in the Merchant Banking Group at Kidder Peabody, and Engagement Manager at the international consulting firm, McKinsey & Company.

"Bob Gay's extensive financial and management capabilities developed with leading companies such as Bain Capital and GE bring further experienced management perspective to our already distinguished board" said Mr. Crocker. "We are excited to have Bob on our team and feel that his insight from previous transactions, growth management, and organizational development will be invaluable as we work toward building a successful company."

Dr. Gay is a member of the Executive Committee of the President's Leadership Council of Brigham Young University (BYU) and a member of the national Advisory Council of the Marriott Business School at BYU. He has taught economics at Harvard University where he also received a Ph.D. in Business Economics and the Harvard Business School Division of Research Scholarship.

Dr. Gay joins Board members Gary Crocker, President of Crocker Ventures, James Dresser, Chairman of the Board of Trustees of Wesleyan University and former Chief Administrative Officer at the Boston Consulting Group, Gordon Fehr, former Chairman and President of Pfizer Canada, Peter Lewis, President of Wharton Equity Partners, LLC, Walter Lovenberg, PhD, President of Lovenberg Associates and former Chief of the Section of Biochemical Pharmacology at the National Institutes of Health, Anthony Sinskey, PhD, co-Founder of Merrimack and Professor of Microbiology in the Biology Department at MIT and Robert Mulroy, President and CEO of Merrimack Pharmaceuticals.

Merrimack Pharmaceuticals, Inc., is a biotechnology company focused on the discovery and development of novel treatments for diseases in the areas of autoimmune disease and cancer. Its lead compound, MM-093, is currently in clinical development to treat patients with rheumatoid arthritis or with autoimmune uveitis. MM-093 is an investigational drug and has not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and safe therapeutics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit

Contact: Kathleen Petrozzelli, Manager, Corporate Communications,


SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
(Date:12/1/2015)... Clara, CA (PRWEB) , ... December 01, 2015 ... ... Force Microscopy (AFM) announces Park NX10 SICM Module, an add-on scanning ion conductance ... easily integratesthe power of SICM to an AFM. , Park SICM benefits virtually ...
(Date:12/1/2015)... DIEGO , December 1, 2015 Dr. Harry Lander ... serving as Chief Science Officer and recruits ... Dr. Harry Lander , President of Regen, expands his role to ... and recruits five distinguished scientists to join ... Regen, expands his role to include serving ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells ... stages of a new closed system for isolating adipose-derived stem cells. The announcement starts ... (SVF) of adipose tissue. SVF is a component of the lipoaspirate obtained from liposuction ...
(Date:11/30/2015)... Partnership includes an MPP ... the u niversity , s Solid Drug Nanoparticle (SDN) ... - up through cost cuts ... , where licensees based anywhere in the world will have the right to make, ... Africa , where licensees based anywhere in the world will have the right ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015 NXTD ) ... focused on the growing mobile commerce market and ... StackCommerce, a leading marketplace to discover and buy ... smart wallet on StackSocial for this holiday season. ... the "Company"), a biometric authentication company focused on ...
(Date:10/27/2015)... Oct. 27, 2015 Synaptics Inc. (NASDAQ: SYNA ... that Google has adopted the Synaptics ® ClearPad ... to power its newest flagship smartphones, the Nexus 5X ... --> --> Synaptics ... provide strategic collaboration in the joint development of next ...
(Date:10/23/2015)... Research and Markets ( ) has announced the ... 2015-2019" report to their offering. ... recognition biometrics market to grow at a CAGR of ... --> The report, Global Voice Recognition Biometrics ... market analysis with inputs from industry experts. The report ...
Breaking Biology News(10 mins):